Cellarity
Cellarity is a clinical-stage biotechnology company developing oral Cell State-Correcting small molecule therapeutics through an AI-powered multi-omics and single-cell transcriptomics platform, with lead candidate CLY-124 in Phase 1 for sickle cell disease.
- Company typePrivate
- Founded2019
- HeadquartersSomerville, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellarity does
Cellarity is a clinical-stage biotechnology company founded in 2019 by Flagship Pioneering, headquartered in Cambridge, Massachusetts, with an additional office in Somerville, MA. The company is developing oral "Cell State-Correcting" small molecule therapeutics that aim to restore proper cell function by precisely regulating gene-switch mechanisms, rather than modulating single molecular targets as in conventional drug discovery. Its core technology is a multi-omics AI-powered discovery platform that integrates high-dimensional single-cell transcriptomics, surface receptor and chromatin accessibility data, and proprietary deep learning foundation models (including ToxPredictor for safety prediction and DrugReflector for active-learning phenotypic screening) to map disease biology and predict chemical interventions. The platform has demonstrated 13- to 17-fold higher recovery of phenotypically active compounds compared with industry-standard approaches.
Cellarity's lead asset, CLY-124, is a first-in-class DCN1 inhibitor and oral globin-switching therapeutic for sickle cell disease that entered a global Phase 1 clinical trial in June 2025 following FDA IND clearance, with 28-day proof-of-concept data expected in Q4 2026. The pipeline additionally includes a JAK2V617F-selective program for myelofibrosis and partnered programs with Novo Nordisk in MASH and with Pioneering Medicines in inflammatory bowel disease. The company is pre-revenue, monetizes through eventual product sales and/or licensing/royalty arrangements with pharmaceutical partners, and has raised $274 million in total funding, most recently a $121 million Series C in October 2022 led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact Partners.
Cellarity firmographics
Firmographics- Name
- Cellarity
- Legal name
- Cellarity, Inc.
- Website
- https://cellarity.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cellarity is a clinical-stage biotechnology company developing oral Cell State-Correcting small molecule therapeutics through an AI-powered multi-omics and single-cell transcriptomics platform, with lead candidate CLY-124 in Phase 1 for sickle cell disease.
- Ownership category
- akta.pro rank
Cellarity industry classification
Industry- Product category
- Biopharmaceuticals (Cell State-Correcting Therapeutics)
- akta.pro primary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where Cellarity is headquartered
LocationHeadquarters
- HQ city
- Somerville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cellarity business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical stage company developing novel therapeutics. Revenue will be generated through eventual product sales following regulatory approval, with potential licensing or partnership arrangements with pharmaceutical companies for development and commercialization rights.
- Strategic Partnerships and Collaborations: Research collaborations and partnerships with pharmaceutical companies such as Novo Nordisk for MASH program and Pioneering Medicines for IBD, potentially generating milestone payments and royalties.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Cellarity product offering
Product offeringCore offering
Cellarity is a clinical-stage biotechnology company that discovers and develops cell state-correcting therapeutics using a proprietary multi-omics AI platform built on high-dimensional single-cell transcriptomics and deep-learning models. Its lead asset CLY-124, an oral first-in-class DCN1 inhibitor for sickle cell disease, is currently in Phase 1 clinical trials, with additional pipeline programs in myelofibrosis, MASH, and IBD executed via strategic partnerships.
Product overview
Cellarity is a clinical-stage biotechnology company pioneering a fundamentally new approach to drug discovery that corrects whole cell-state dysfunction to solve complex diseases. The company's proprietary platform integrates advanced transcriptomics with AI predictive modeling to discover and develop oral Cell State-Correcting therapeutics. The lead product, CLY-124 (a first-in-class DCN1 inhibitor for sickle cell disease), is in Phase 1 clinical trials. The company is also advancing programs in myelofibrosis and has partnerships with Novo Nordisk for MASH and Pioneering Medicines for IBD.
Differentiator
Problem solved
Functional benefit
Products and services
- CLY-124 CLY-124 is a first-in-class oral DCN1 inhibitor and globin-switching therapy designed to increase fetal hemoglobin (HbF) early in red blood cell maturation. It is being developed for sickle cell disease and is currently in Phase 1 clinical development, with the goal of providing best-in-class HbF induction without cytotoxicity.
Quantifiable outcome
- 13- to 17-fold higher hit rates in drug discovery compared to industry standard approaches
- +4 more outcomes
Companies that use Cellarity
Customer profileSegments4 records
Ideal customer profiles2 records
Cellarity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Cellarity partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major.
- Novo NordiskmajorStrategic partnership addressing novel biologic insights in Metabolic Dysfunction-Associated Steatohepatitis (MASH). This is Cellarity's first example of a partnered program applying its disruptive approach to areas of strategic interest to a partner company. The collaboration advances Cellarity's platform application in metabolic disorders.
- Pioneering MedicinesmajorResearch collaboration with Pioneering Medicines to develop novel, small molecule therapeutics for inflammatory bowel disease (IBD). Leverages Cellarity's platform capabilities for immune disorders.
Scale indicators5 records
Recent moves8 records
Expansion highlights4 records
Cellarity competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Recursion is an AI-native drug discovery company combining high-dimensional phenomics, transcriptomics and deep learning to identify novel therapeutics. Cellarity overlaps directly on the high-dimensional transcriptomics + foundation-model approach and competes for the same pharma collaboration and talent pool.
- Insitro: Insitro builds ML models on patient-derived cellular data to discover and develop therapeutics for metabolic and neurological diseases. Like Cellarity, it is a privately-backed AI/ML platform biotech that partners with major pharma (e.g., Lilly, Gilead) and pursues clinical-stage assets.
- Exscientia: Exscientia is an AI-driven precision drug design company that has multiple pharma collaborations and pipeline programs progressing through the clinic. It is directly comparable in business model (AI platform + pipeline + pharma BD) and customer base to Cellarity.
- Schrödinger: Schrödinger combines computational chemistry, physics-based modeling and ML to discover therapeutics, and licenses its platform to pharma while running an internal pipeline. Mirrors Cellarity's dual platform-plus-pipeline biotech model.
- Isomorphic Labs: Isomorphic Labs is Alphabet's AI-first drug design company building on AlphaFold and partner programs with Novartis and Lilly. Closely comparable AI-driven drug discovery approach and deal-based business model; competes for similar pharma partnerships.
- Generate Biomedicines: Generate Biomedicines applies generative AI to design novel therapeutics across modalities. Like Cellarity, it is a US-based platform biotech founded by a top-tier life-sciences creator (Flagship Pioneering) with a multi-program pipeline and pharma partnership strategy.
- AbCellera Biologics: AbCellera operates an AI-enabled antibody discovery platform that partners with pharma to originate programs while also advancing internal pipeline candidates. Comparable on platform-plus-pipeline model, biotech BD model, and clinical-stage ambitions.
- Verge Genomics: Verge Genomics applies ML to human omics datasets (including transcriptomics) to identify drug targets and develop therapeutics for neurodegenerative diseases. Comparable AI + multi-omics platform approach, though focused on CNS indications.
Broad incumbents
- Owkin: Owkin is an AI/biopharma company using multimodal patient data and foundation models for drug discovery and diagnostics, with pharma partnerships across multiple therapeutic areas. Overlaps with Cellarity's data + AI platform narrative but spans a wider portfolio including diagnostics.
Emerging players
- BPGbio: BPGbio applies AI to interrogate biological pathways and develop oncology and metabolic therapeutics, with an assets-in-development pipeline. Partial overlap with Cellarity's multi-omics discovery approach and partnered-program business model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cellarity social profiles
Digital presenceCellarity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellarity leadership team
Management profileNumber of profiles
Profiles22 records
Cellarity funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellarity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellarity
What does Cellarity do?
Cellarity is a clinical-stage biotechnology company that discovers and develops cell state-correcting therapeutics using a proprietary multi-omics AI platform built on high-dimensional single-cell transcriptomics and deep-learning models. Its lead asset CLY-124, an oral first-in-class DCN1 inhibitor for sickle cell disease, is currently in Phase 1 clinical trials, with additional pipeline programs in myelofibrosis, MASH, and IBD executed via strategic partnerships.
Is Cellarity a public or private company?
Cellarity is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellarity founded?
Cellarity was founded in 2019. It employs 101 to 250 people.
Where is Cellarity based?
Cellarity is headquartered in Somerville, United States, in the North America region.
How does Cellarity make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are strategic Partnerships and Collaborations.
Who are Cellarity's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Schrödinger, Isomorphic Labs, Generate Biomedicines, AbCellera Biologics and Verge Genomics. Owkin is listed as a broad incumbent. BPGbio is listed as an emerging player.
Does Cellarity have an API?
No public API is recorded for Cellarity.
What industry is Cellarity in?
Cellarity's product category is Biopharmaceuticals (Cell State-Correcting Therapeutics). Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening).